Glutamic Acid

Glutamic Acid

SCHEMBL639610

CN.N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.90
GRM6 O15303 2/20 0.90
GRM7 Q14831 2/20 0.90
GRM4 Q14833 2/20 0.90
CYP1A2 P05177 2/20 0.90
GRIN2D O15399 1/20 0.90
GRIN3B O60391 1/20 0.90
GSR P00390 1/20 0.90
GRIK1 P39086 1/20 0.90
GRM5 P41594 1/20 0.90
GRIA1 P42261 1/20 0.90
GRIA2 P42262 1/20 0.90
GRIA3 P42263 1/20 0.90
SLC1A3 P43003 1/20 0.90
SLC1A2 P43004 1/20 0.90
SLC1A1 P43005 1/20 0.90
GRIA4 P48058 1/20 0.90
GRIN1 Q05586 1/20 0.90
GRIN2A Q12879 1/20 0.90
GRIK2 Q13002 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL27721208 1.00 GRM8 (0.90) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL9449715 1.00 GRM8 (0.90) GRM8GRM6GRM7GRM4CYP1A2
Glutamic Acid SCHEMBL7965611 0.95 GRM8 (0.90) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL1332297 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL1330824 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
Glutamic Acid SCHEMBL5704264 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL17127348 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL1330484 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
Glutamic Acid SCHEMBL1554237 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2
D-Glutamate SCHEMBL931953 0.95 GRM8 (1.00) GRM8GRM6GRM7GRM4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017075485-A1 BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH TRIMETHYLAMINE (TMA) IS DETRIMENTAL SYNLOGIC, INC. (US) 2017-05-04 WO disclosed
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM BP CORP NORTH AMERICA INC (US) 2015-08-27 US disclosed
US-8962800-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2015-02-24 US disclosed
US-20120266329-A1 Nucleic Acids and Proteins and Methods for Making and Using Them BP CORPORATION NORTH AMERICA INC. (US) 2012-10-18 US disclosed
US-8119385-B2 Nucleic acids and proteins and methods for making and using them BP CORPORATION NORTH AMERICA INC. (US) 2012-02-21 US disclosed
US-20110296543-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM THE UNIVERSITY OF CALIFORNIA (US) 2011-12-01 US disclosed
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them VERENIUM CORPORATION (US) 2010-01-14 US disclosed
US-7635572-B2 Methods for conducting assays for enzyme activity on protein microarrays Life Technologies Corporation (US) 2009-12-22 US disclosed
EP-1642109-A4 METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS PROTOMETRIX INC (US) 2007-09-05 EP disclosed
EP-1642109-A2 METHODS FOR CONDUCTING ASSAYS FOR ENZYME ACTIVITY ON PROTEIN MICROARRAYS Protometrix, Inc. (US) 2006-04-05 EP disclosed
US-20050118665-A1 Methods for conducting assays for enzyme activity on protein microarrays PROTOMETRIX, INC. 2005-06-02 US disclosed
WO-2005003721-A2 ENZYME ACTIVITY ASSAYS ON PROTEIN MICROARRAYS PROTOMETRIX, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150240226-A1 NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM POLN, POLM, POLI GRM8 4155/4885GRM6 3776/4885GRM7 4148/4885
US-20120266329-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI GRM8 4155/4885GRM6 3776/4885GRM7 4148/4885
US-20100011456-A1 Nucleic Acids and Proteins and Methods for Making and Using Them POLN, POLM, POLI GRM8 4155/4885GRM6 3776/4885GRM7 4148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.